Enterome's EO2463 Receives FDA Fast Track Designation for Follicular Lymphoma Watch-and-Wait Treatment
核心洞察
The FDA has granted Fast Track designation to Enterome's EO2463, a first-in-class OncoMimics (搜索) immunotherapy for follicular lymphoma (搜索) patients in the low tumor burden "watch-and-wait" setting.
EO2463 demonstrated marked efficacy as a monotherapy with excellent safety and tolerability in interim data from the ongoing Phase 2 SIDNEY trial.
The innovative therapy combines four synthetic peptides that mimic B cell markers CD20 (搜索), CD22 (搜索), CD37 (搜索), and CD268 (搜索), designed using AI and machine learning from 23 million bacterial genes.
Enterome announced that the U.S. Food and Drug Administration has granted Fast Track designation for its lead OncoMimics (搜索) immunotherapy EO2463 in follicular lymphoma (搜索) patients with low tumor burden in the "watch-and-wait" setting. The designation recognizes EO2463's potential to address a significant unmet medical need for patients who currently receive no treatment despite having a progressive cancer diagnosis.
Addressing an Unmet Medical Need
The Fast Track designation covers follicular lymphoma (搜索) patients in the watch-and-wait setting, where individuals are diagnosed with cancer that progresses in the vast majority of cases but show no troublesome symptoms and do not normally receive treatment. Pierre Belichard, CEO of Enterome, stated that "The FDA's decision is an important validation of the unique potential of Enterome's OncoMimics (搜索) program. It will expedite the clinical development and the regulatory pathways for EO2463, which is ready to enter registrational testing as early as next year."
Follicular lymphoma (搜索) is one of several types of indolent Non-Hodgkin lymphoma (搜索), characterized as an incurable chronic condition with frequent relapses, slow progression and few symptoms, yet reduced life expectancy. The disease is usually diagnosed by swollen lymph nodes, and early stages can be characterized by a lack of troublesome symptoms such as night sweats, fever or weight loss. There is widespread consensus among leading investigators of the need for a well-tolerated and effective monotherapy to stop or slow progression for watch-and-wait patients.
Clinical Development Progress
EO2463 is ready for Phase 3 testing in watch-and-wait patients after showing marked efficacy as a monotherapy in interim data from the watch-and-wait population in the ongoing Phase 2 SIDNEY trial. The treatment was well tolerated, suggesting the immunotherapy may offer a safe and effective treatment option for patients in this setting. Enterome plans to start a registrational Phase 3 watch-and-wait trial in 2026.
The Fast Track designation provides increased opportunities for interaction with the FDA, rolling review and potential eligibility for priority review, following a recent positive type-C meeting with the FDA.
Novel OncoMimics Technology
EO2463 is an innovative, off-the-shelf OncoMimics (搜索) active immunotherapy that combines four synthetic peptides. These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with B lymphocyte-specific lineage markers CD20 (搜索), CD22 (搜索), CD37 (搜索), and CD268 (搜索) (BAFF receptor (搜索)). The therapy also includes the helper peptide (CD4+ epitope) universal cancer peptide 2 (UCP2).
The unique ability of EO2463 to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes. By ensuring broad target coverage across malignant B cells, this approach aims to simultaneously improve safety and maximize efficacy, reducing tumor cells' capacity to develop immune-resistance mechanisms such as antigen escape.
OncoMimics (搜索) are bacteria-derived peptide antigens that closely mimic tumor-associated antigens or lineage markers. These synthetically produced peptides are designed in silico using AI and machine learning to mine Enterome's extensive proprietary database of 23 million commensal bacteria genes. Because these peptides are "non-self," they tap into pre-existing pools of effector-memory CD8 T cells primed by gut bacteria, enabling rapid, strong, and durable anti-tumor responses while avoiding the self-tolerance that limits many cancer immunotherapies.
Manufacturing and Safety Profile
OncoMimics (搜索) are easy to manufacture, store, distribute and administer as an "off-the-shelf" subcutaneous injection. In clinical testing to date, they have been shown to be extremely well tolerated, especially compared to other potent immunotherapies.
Enterome's three most advanced product candidates have shown positive early data in Phase 2 clinical development in more than 230 patients across solid tumors and hematological malignancies, demonstrating correlation between clinical efficacy and induced immunogenicity with a very favorable safety profile with no systemic adverse events, activating large quantities of endogenous memory T-cells without inducing cytokine release syndrome.